Herbert Smith Freehills’ venture capital team has advised Rosemary Health on its Series Seed capital raise.
Rosemary Health is telehealth platform that facilitates electronic prescriptions and prescription deliveries to Australian consumers.
This new capital will be employed to accelerate the growth and market penetration of its range of asynchronous telehealth clinics. The round was led by early stage VC fund, Artesian Venture Partners, with investors in the round including US VC fund Breyer Capital.
The Herbert Smith Freehills team was led by Partner and Head of Venture Capital Peter Dunne and Solicitor Myra Beal.
Myra Beal said, “Rosemary Health is a great example of an Australia technology company addressing an important unmet need for Australian consumers. With the COVID-19 pandemic, it is more important than ever that Australians have access to telehealth and medicines from their homes. It was great to work with Romain and the Rosemary Health team on this capital raise and look forward to seeing the Company’s next steps.”
Rosemary Health Founder and CEO, Romain Bonjean, said, “The team at Herbert Smith Freehills has been a pleasure to work with, and made this cross-border raising fast and efficient.”
This capital raise continues Herbert Smith Freehills’ partnership with Rosemary Health, with the firm having previously acted on the company’s convertible note capital raise in May 2019 as well as their PoPs healthcare acquisition in early 2020.
This deal is another example of Herbert Smith Freehills’ market-leading work in the Australian technology sector and Australian venture capital. Other recent examples include:
- Kasada on its A$15 million Series B capital raise;
- SafetyCulture on its A$60.5 million Series C1 capital raise and secondary sale;
- Different Technologies on its A$7.1 million series A capital raise;
- Culture Amp on its A$120 million Series E capital raise; and
- Expert360 on its A$12 million Series C capital raise.